Surgical Science Sweden ABSUSRF -2.20%82 Return-on-Tangible-Equity is 8.14% as of Mar. 2026, which is 54% below its 10-year median of 17.52. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.30 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 582 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks worse than 60.14% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Surgical Science Sweden AB's annualized net income for the quarter that ended in Mar. 2026 was $8.0 Mil. Surgical Science Sweden AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $98.3 Mil. Therefore, Surgical Science Sweden AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 8.14%.
The historical rank and industry rank for Surgical Science Sweden AB's Return-on-Tangible-Equity or its related term are showing as below:
SUSRF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -13.07 Med: 17.52 Max: 48.02
Current: 6.03
During the past 11 years, Surgical Science Sweden AB's highest Return-on-Tangible-Equity was 48.02%. The lowest was -13.07%. And the median was 17.52%.
SUSRF's Return-on-Tangible-Equity is ranked worse than 60.14% of 582
companies
in the Healthcare Providers & Services industry
Industry Median: 9.965
vs SUSRF: 6.03
Surgical Science Sweden AB (OTCPK:SUSRF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Surgical Science Sweden AB Return-on-Tangible-Equity Related Terms
Surgical Science Sweden AB Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Return-on-Tangible-Equity Chart
SUSRF vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.14% mean?
Surgical Science Sweden AB (SUSRF) has a Return-on-Tangible-Equity of 8.14% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Surgical Science Sweden AB and its competitors. This is 54% below median its historical median of 17.52. According to the industry distribution chart, Surgical Science Sweden AB ranks #350 out of 582 companies in the Healthcare Providers & Services industry, placing it in the top 60.1%.
Is Surgical Science Sweden AB's Return-on-Tangible-Equity too high?
Surgical Science Sweden AB's current Return-on-Tangible-Equity of 8.14% is 54% below median its 10-year median of 17.52. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 9.97. Surgical Science Sweden AB's value of 8.14% is 18.3% below this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #350 out of 582 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #350 out of 582 companies for Return-on-Tangible-Equity. This places Surgical Science Sweden AB in the lower half of its industry. The industry median Return-on-Tangible-Equity is 9.97. Surgical Science Sweden AB's value of 8.14% is 18.3% below this benchmark. While the company's 10-year median is 17.52 vs. the industry median of 9.97, Surgical Science Sweden AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 9.97, based on 582 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Return-on-Tangible-Equity of 8.14% is 18.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 9.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Return-on-Tangible-Equity is 8.14%, which is 54% below median its own 10-year median of 17.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.30, compared to a current price of $4.00 — trading 72% below its estimated fair value. The current Return-on-Tangible-Equity is 8.14%, which is 54% below median its 10-year median of 17.52 and 18.3% below the Healthcare Providers & Services industry median of 9.97. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Return-on-Tangible-Equity is 8.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 72% below its estimated GF Value™ of $14.30.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Return-on-Tangible-Equity: 8.14% (54% below median its 10-year median of 17.52)
GF Value™: $14.30 vs. price of $4.00 (72% below fair value)
Industry Position: 18.3% below the Healthcare Providers & Services median (#350 of 582)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
